Engineering exosomes to either block or reverse TGF-β1-mediated immunosuppression—such as loading antagonists or small interfering RNAs against TGF-β signaling—may offer a novel therapeutic avenue in overcoming immune evasion and restoring anti-tumor immunity in osteosarcoma (56). The gene discussed is TGFB1; the disease is osteosarcoma.